Recent Updates
Recently added Catalysts
NPCE Positive Sentiment Score: 70/100

NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

Key Takeaway: NeuroPace, Inc. (Nasdaq: NPCE) has announced that it will report its financial results for the fourth quarter and full year of 2022 on March 2, 2023. The report will be followed by a conference call, beginning at 1:30 p.m. Pacific Time. NeuroPace specializes in medical devices aimed at managing epilepsy, notably through its RNS System, which delivers personalized treatments to patients. The webcast will be accessible for live and archived viewing for investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • NeuroPace is focused on transforming the lives of people with epilepsy.
  • The company offers a novel brain-responsive treatment for drug-resistant epilepsy.
  • Upcoming financial report may provide insights into the company’s growth and performance.

Full Press Release Details

MOUNTAIN VIEW, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 2, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.neuropace.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Frequently Asked Questions

When will NeuroPace report its 2022 financial results?

NeuroPace will report its 2022 financial results on March 2, 2023.

What time is the NeuroPace conference call scheduled?

The conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET.

How can investors access the NeuroPace conference call?

Investors can access the webcast at www.neuropace.com on the Investors page.

What is the RNS System used for?

The RNS System helps reduce or eliminate seizures in epilepsy patients.

How long will the conference call replay be available?

The replay of the conference call will be available for at least 90 days.

Last updated: Feb 10, 2023